Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results.

Epidemiology and infection·2019
Same author

Bcl-2/caspase 3 mucosal imbalance favors T cell resistance to apoptosis in dogs with inflammatory bowel disease.

Veterinary immunology and immunopathology·2014
Same author

Neurochemical evidence for a nigrotegmental GAbAergic projection.

Brain research·2013
Same author

Effects of transcranial focal electrical stimulation via tripolar concentric ring electrodes on pentylenetetrazole-induced seizures in rats.

Epilepsy research·2013
Same author

Critical research needs for managing coral reef marine protected areas: perspectives of academics and managers.

Journal of environmental management·2012
Same author

Neonatal exposure to phenobarbital potentiates schizophrenia-like behavioral outcomes in the rat.

Neuropharmacology·2012

Related Experiment Video

Updated: Jul 13, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

W H Likosky1, B Fireman, R Elmore

  • 1Department of Neurology, Kaiser Permanente Medical Center, Santa Clara, CA 95051.

Journal of Neurology, Neurosurgery, and Psychiatry
|December 1, 1991
PubMed
Summary

A randomized trial found that a short course of immunosuppression with cyclophosphamide did not stabilize chronic progressive multiple sclerosis (MS). Disease progression was similar in patients receiving cyclophosphamide and those receiving folic acid.

More Related Videos

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: Jul 13, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

  • Neurology
  • Immunology

Background:

  • Chronic progressive multiple sclerosis (MS) is a debilitating neurological disease.
  • Effective treatments for stabilizing MS progression remain a critical unmet need.

Purpose of the Study:

  • To evaluate the efficacy of a short course of intensive immunosuppression with cyclophosphamide in stabilizing chronic progressive multiple sclerosis.
  • To assess the impact of cyclophosphamide on disability, functional systems, and social roles in MS patients.

Main Methods:

  • A randomized, single-blinded, placebo-controlled trial involving 42 patients with chronic progressive MS.
  • Patients received either cyclophosphamide (n=22) until leucocyte counts fell below 4000/mm3 or folic acid (n=20) as a placebo.
  • Assessments of disability, functional impairment, and social role performance were conducted at baseline and at 12, 18, and 24 months post-therapy.

Main Results:

  • The primary endpoint at 12 months showed a similar mean increase in disability (0.5 on Kurtzke's Expanded Disability Status Scale) in both the cyclophosphamide and folic acid groups.
  • No substantial benefits were observed in the cyclophosphamide group compared to the placebo group regarding disease stabilization.
  • Immunosuppression with cyclophosphamide was safely administered in an outpatient setting.

Conclusions:

  • A short course of intensive immunosuppression with cyclophosphamide did not demonstrate significant efficacy in stabilizing chronic progressive multiple sclerosis.
  • While safe for outpatient administration, cyclophosphamide did not provide substantial therapeutic benefits for MS progression in this study.